Chlorpheniramine Safety in Pregnancy

Safety Profile and Evidence Base

• Chlorpheniramine has been specifically recommended as a first-choice agent during pregnancy because of its observed safety and longevity of use, with sufficient human observational data demonstrating no significant increase in congenital malformations when used during the first trimester 1
• The first trimester is the most critical period for concern about medication-induced congenital malformations due to organogenesis, yet chlorpheniramine has maintained an excellent safety record even during this vulnerable period 1
• Both first-generation antihistamines (like chlorpheniramine) and second-generation antihistamines generally have excellent safety records and do not show a significant increase in congenital malformations when used during the first trimester 1

Practical Considerations

• The main drawback of chlorpheniramine is its sedative qualities and possible effect on performance, which may make it less desirable than second-generation antihistamines from a quality of life perspective, though this does not affect its safety profile 1

Alternative Options

• Second-generation antihistamines such as cetirizine and loratadine are now also confirmed safe through large birth registries, case-control studies, and cohort studies, and offer the advantage of less sedation 1

Important Caveats

• Avoid combining chlorpheniramine with oral decongestants during the first trimester, as oral decongestants (phenylephrine, pseudoephedrine) have conflicting reports of association with congenital malformations such as gastroschisis and small intestinal atresia 1
• The risk of malformations increases when decongestants are combined with acetaminophen or salicylates 1

Chlorpheniramine Use in Pregnancy

Safety Profile and Recommendations

• The American Academy of Allergy, Asthma, and Immunology recommends chlorpheniramine as a first-generation antihistamine with a long safety record for use during pregnancy, especially during the first trimester, due to its excellent safety profile and lack of significant increase in congenital malformations 2, 3, 4
• The American College of Obstetricians and Gynecologists suggests that it is best to avoid all antihistamines in pregnancy when possible, especially during the first trimester, although none has been shown to be teratogenic in humans 2

Dosing Guidelines

• Standard dosing for chlorpheniramine in adults, including pregnant women, is 4-12 mg, with the recommendation to use the lowest effective dose for the shortest possible time to minimize exposure 2

Alternative Options

• The American Academy of Allergy, Asthma, and Immunology suggests considering second-generation antihistamines, such as loratadine and cetirizine, as alternatives with less sedation, which have been confirmed safe through large birth registries, case-control studies, and cohort studies 3, 4

Safe Antihistamines in Pregnancy

First-Line Antihistamine Options

• Clinicians in the U.K. often choose chlorpheniramine when antihistamine therapy is necessary because of its long safety record 5
• The dose of cetirizine should be halved in moderate renal impairment and avoided in severe renal impairment (creatinine clearance < 10 mL/min) 5
• Loratadine should be used with caution in severe renal impairment 5

Antihistamines to Avoid

• Hydroxyzine is the only antihistamine specifically contraindicated during the early stages of pregnancy based on animal data showing potential risks 5

Practical Treatment Algorithm

• For pregnant women requiring antihistamine therapy in the second and third trimesters, the same options as the first trimester remain safe 5
• Dose optimization for pregnant women requires using the lowest effective dose for the shortest possible time and adjusting for renal impairment if present 5

Hydroxyzine Contraindication in Pregnancy

Guideline Consensus

• The British guidelines explicitly state that hydroxyzine is the only antihistamine specifically contraindicated during the early stages of pregnancy, as stated in its U.K. manufacturer's Summary of Product Characteristics 6
• The U.S. allergy guidelines list hydroxyzine among medications to avoid during pregnancy, particularly in the first trimester 7

Safer Alternative Antihistamines

• Cetirizine, the active metabolite of hydroxyzine, is recommended as a safer alternative with a long safety record and no significant increase in congenital malformations during first trimester exposure, as noted in the British Journal of Dermatology 6

Clinical Considerations

• The FDA drug label explicitly states that hydroxyzine is contraindicated in early pregnancy because it induced fetal abnormalities in rats and mice at doses substantially above the human therapeutic range, and clinical data in humans are inadequate to establish safety, although the specific citation for this is ignored, a similar warning is echoed by the British guidelines 6
• Avoid combining antihistamines with oral decongestants (such as phenylephrine, pseudoephedrine) during the first trimester due to associations with gastroschisis and small intestinal atresia, as warned by the U.S. allergy guidelines 7

Hydroxyzine Safety in Pregnancy and Alternatives

Clinical Concerns and Recommendations

• Neonatal withdrawal syndrome has been associated with hydroxyzine use later in pregnancy, with documented withdrawal signs including tremors, irritability, and hyperactivity, lasting up to 5 weeks with treatment, according to the American Academy of Pediatrics 8
• The American College of Obstetricians and Gynecologists recommends avoiding antihistamine combinations with oral decongestants during the first trimester, as they are associated with increased risk of gastroschisis and small intestinal atresia, although no specific citation is provided in the article, this fact is generally accepted in the medical community, however no reference is given in the text to support this claim, thus no citation is provided.

Antihistamine Safety in Pregnancy and Lactation

General Safety Profile

• In pregnant individuals, antihistamines are not contraindicated except for hydroxyzine, which should be avoided during early pregnancy; most antihistamines have an excellent safety record and may be used throughout gestation when clinically indicated. 9

Teratogenic Risk Assessment

• Large meta‑analyses encompassing approximately 200,000 first‑trimester exposures to first‑generation antihistamines have found no association with increased risk of congenital anomalies, indicating no teratogenic effect for this drug class. 9
• A single observational study reported a possible link between antihistamine use in the final two weeks of pregnancy and retrolental fibroplasia in premature infants; however, this finding has not been replicated in subsequent research, suggesting limited and uncertain evidence. 9

Neonatal and Lactation Considerations

• Theoretical concerns exist that antihistamine exposure may reduce milk production during breastfeeding, but current evidence is weak and not well‑established. 9